Table 4.

Association between baseline hs-cTnT and myocardial scar at follow-up, among those with gadolinium-enhanced CMR at follow-up (N=1723)

hs-cTnT category (ng/L)*	Unadjusted	Age, sex, race	+ risk factors†, LV mass, and LVEF
<LOD	Reference	Reference	Reference
3.0–3.97	1.68 (0.75, 3.77)	1.31 (0.57, 3.02)	1.29 (0.54, 3.09)
3.98–5.32	2.67 (1.30, 5.48)	1.86 (0.88, 3.95)	1.77 (0.80, 3.88)
5.33–7.41	5.34 (2.85, 10.02)	3.31 (1.68, 6.54)	2.49 (1.20, 5.15)
≥7.42	6.68 (3.63, 12.28)	3.26 (1.63, 6.51)	2.41 (1.15, 5.06)
Test for trend	<.001	<.001	.007
ln(hs-cTnT)	2.77 (2.11, 3.63)	1.87 (1.38, 2.54)	1.57 (1.12, 2.17)

^*Categories based on distribution of hs-cTnT among those with gadolinium-enhanced-CMR at visit 5

^†SBP, DBP, anti-hypertensive medications, diabetes (normal/DM), smoking, lipids, height, weight, and estimated GFR.

Cell Values represent Odds Ratios and 95% CI